InterMune (NASDAQ:ITMN) shares fell 13% to $13.24 after news broke that a significant trial for its drug Esbriet was postponed.Last week, the company announced it didn’t expect enrollment for the Phase III clinical trial to be finish by the end of the year, when the company predicted enrollment to be finish by the second quarter.InterMune (NASDAQ:ITMN) has potential upside of 119.3% based on a current price of $12.7 and an average consensus analyst price target of $27.85.
